Navigation Links
Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008
Date:2/5/2009

current assets 538,987 1,129,300 Total current assets 150,928,674 166,245,152 Marketable securities, at fair value 4,486,834 - Property and equipment, net 14,225,397 1,250,437 Other assets 7,515 111,074 Total assets $169,648,420 $167,606,663 Liabilities and Stockholders' Equity Liabilities: Note payable $6,000,000 $- Accounts payable 3,247,051 1,987,579 Accrued liabilities 4,614,121 12,606,422 Deferred revenue 6,166,246 5,789,936 Total current liabilities 20,027,418 20,383,937 Deferred taxes 2,815,577 2,533,220 Total liabilities $22,842,995 $22,917,157 Stockholders' equity: Preferred stock, $.01 par value- Authorized - 1,500,000 shares Issued - none - - Common stock, $.01 par value- Authorized - 45,000,000 shares Issued - 18,479,345 and 18,442,846 shares, respectively 184,794 184,429 Additional paid-in capital 205,306,957 199,988,081 Accumulated other comprehensive (loss) income (542,443) 12,590 Accumulated deficit (52,547,173) (52,479,008) Treasury stock, at cost - 413,255 and 105,000 shares, respectively (5,596,710) (3,016,586) Total stockholders' equity $146,805,425 $144,689,506 Total liabilities and stockholders' equity
'/>"/>
SOURCE Palomar Medical Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Palomar Medical Technologies Third Quarter 2007 Financial Results Conference Call and Webcast
2. Palomar and Gillette Extend Launch Decision on Home-Use Light Based Hair Removal Device and Agree to Negotiate New Terms
3. Palomar to Debut New Technology at the American Academy of Dermatology Annual Meeting
4. Palomar Seeks to License Additional Companies to Home-Use Light-Based Hair Removal Technology
5. Palomar to Unveil New Laser-Assisted Liposuction Platform at the American Society for Laser Medicine & Surgery
6. Palomar Medical Technologies to Host Second Quarter 2008 Financial Results Conference Call and Webcast on July 31, 2008
7. Palomar Medical Reports Financial Results for Third Quarter 2008
8. Palomar Medical Technologies and Reliant Technologies Announce Launch of a Fractional Technology Licensing Program
9. Reliant Technologies, and Palomar Medical Technologies, Announce Launch of a Fractional Technology Licensing Program
10. Palomar Medical Technologies to Host Fourth Quarter and Year End 2008 Financial Results Conference Call and Webcast on February 5, 2009
11. MSU engineering team designs innovative medical device

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)... may be left atrial enlargement, study finds , ...y is a major risk factor for left atrial enlargeme...n, stroke and death, a new study shows. , Atria...ia (an irregular heart rhythm or heartbeat). ,... aged 25 to 74, in Germany who were followed for 1...
(Date:11/9/2009)...ikely due to fact that both eye conditions are age...v. 9 (HealthDay News) -- Cataract surgery doesn,t ...ular degeneration (AMD), according to a new study ... of vision loss worsens the other. , "Because b...viduals with cataract also have AMD," wrote Li Min...
(Date:11/9/2009)...y of care increases with longer doctor visits, res...ay News) -- Family doctors are now taking more tim... often and improving the quality of visits, a new ...h their primary care physicians during office visi...and overall they seemed to receive better care," s...
(Date:11/9/2009)... Course, to be Offered in April...oolkit , Cambridge, MA (V...hysicians for Human Rights (PHR) first inspected a...stan , he realized he would need a team of experts...ting the site properly was a key first step in sec...
(Date:11/9/2009)...LEBANON, Tenn., Nov. 9 Health Conn...ounced it will host their inaugural Hospital O.R. ...10 at the Marriott Renaissance Hotel in Nashville,...more than 100 hospital operating room directors an...health systems in the country. Some of the confirm...
Breaking Medicine News(10 mins):Health News:Cataract Surgery Doesn't Worsen Macular Degeneration: Study 2Health News:Doctors Spending More Time Now With Patients 2Health News:Doctors Spending More Time Now With Patients 3Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 2Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 3Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 4Health News:Health Connect Partners Hosts Hospital O.R. & Surgery Center Conference 2
...f money, and ,lack of time, as, the top three fac...hing changes that benefit their ...rom a survey,released today reveal that the vast m...e actually successful. The,survey, commissioned by...
...a precarious time, as about 15 percent of women wh...ry. This risk increases when pregnant women underg...ry (HSS) in New York instituted a same-day pregnan...regnancies to the benefit of the patient, the phys...
...s of Biovail,Corporation (NYSE: BVF )(TSX: BVF) t...EO of Biovail Corporation:, , June 16, 2008, Wil...ration 7150 Mississauga Road Mississauga, Ontari...ovail shareholders have an important decision to m...
...the American Medical Association (AMA), Patrick W....MA,s Council of Ethical and Judicial Affairs,(CEJA...cal and Judicial Affairs (CEJA) develops ethics,po...address timely ethical issues that confront physic...
...of hot flashes that they experience by more than 4...r verbal memory, according to a study by researche...e study is published online and will appear in the... memory performance. , Memory complaints are comm...
... bound for baldness , , MONDAY, June 16 (H...e losing? , Start counting -- the hairs on your c...chives of Dermatology , scientists demonstrate tha...ch can be carried out in the convenience of your o...
Other Medicine News:Health News:LIVESTRONG.COM Survey Reveals 86 Percent of Americans Attempt Changes to Improve Their Health but Less Than Half are Successful 2Health News:LIVESTRONG.COM Survey Reveals 86 Percent of Americans Attempt Changes to Improve Their Health but Less Than Half are Successful 3Health News:LIVESTRONG.COM Survey Reveals 86 Percent of Americans Attempt Changes to Improve Their Health but Less Than Half are Successful 4Health News:Same-day pregnancy test provides valuable guidance to pre-surgery patients 2Health News:Letter Challenges Biovail CEO to a Debate 2Health News:Letter Challenges Biovail CEO to a Debate 3Health News:Hot flashes underreported and linked to forgetfulness 2Health News:Countdown to Hair Loss 2Health News:Countdown to Hair Loss 3
(Date:11/9/2009)...v. 9 /PRNewswire-Asia-FirstCall/ -- American Orien...any" or "AOBO"), a pharmaceutical,company dedicate...ufacture and,commercialization of a broad range of...s, today announced that it plans to release third ... 16, 2009, after the market closes. , The...
(Date:11/9/2009)...N.J., Nov. 9 Par Pharmac...ced that it has extended the expiration date and i...unced "Modified Dutch Auction" tender offer, in wh...65,000,000 aggregate principal amount, or up to ap...r Subordinated Convertible Notes due 2010. ,, T...
(Date:11/9/2009)...9, 2009 Arena Pharmaceut...ial results for the third quarter ended September ...locable to common stockholders in the third quarte...mpared to a net loss allocable to common stockhold... or $0.76 per share, and a net loss allocable to c...
Breaking Medicine Technology:Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Note 2Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Note 3Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 2Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 3Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 4Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 5Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 6Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 7Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 8Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 9Customers Design Reid Supply 26apos 3Bs New Web Site 50846 1Customers Design Reid Supply 26apos 3Bs New Web Site 50846 2Customers Design Reid Supply 26apos 3Bs New Web Site 50846 3Customers Design Reid Supply 26apos 3Bs New Web Site 50846 4Customers Design Reid Supply 26apos 3Bs New Web Site 50846 5MRI accurately depicts deep endometriosis 50842 1MRI accurately depicts deep endometriosis 50842 2SoundBite 28TM 29 Hearing System by Sonitus Medical Receives First Acceptance for Publication in Otology 26 Neurotology Journal 50838 1SoundBite 28TM 29 Hearing System by Sonitus Medical Receives First Acceptance for Publication in Otology 26 Neurotology Journal 50838 2SoundBite 28TM 29 Hearing System by Sonitus Medical Receives First Acceptance for Publication in Otology 26 Neurotology Journal 50838 3
...t and Phase 1b Combination Clinical Trials ...y, SOUTH SAN FRANCISCO, Calif., June 16 Sunesis,...ata Saturday from two,clinical trials of the compa...595), including updated results of a Phase 1 trial...sed or refractory patients with acute,myeloid leuk...
...Pharmaceuticals,Inc. (Amex: ANX ) today provided ... Phase 2b clinical trial of CoFactor for the treat...verall survival results in this,study have been re...fluorouracil) arm demonstrating a 14 day improveme...5-FU arm., "In the Phase 2b study, CoFactor was d...
Other Medicine Technology:Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 2Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 3Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 4Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 5Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 6ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results 2ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results 3
VACUETTE EDTA tubes - Ridged (safety screw cap)
...taminase (tTg) is a ubiquitous enzyme that catalyz...aminase is also the specific protein that is ident...e (EMA) tests (Bio-Rad catalog number 29003 and 29...ighly sensitive and specific for celiac disease di...
...ff gets the training it needs with the NetLearning...nd Human Capital Management System in one. Whether... and HIPAA, understanding compliance reporting for...eloping skills through continuing education course...
Anal Canal EMG Starter Kit
Medicine Products: